AbbVie may commit less capital to psych drugs: report

AbbVie (NYSE:ABBV) reportedly may commit less capital to the development of psychiatric drugs in the wake of its $8.7B acquisition of psychiatric drug developer Cerevel and the failure of a key schizophrenia drug candidate.

“We would be certainly thoughtful, we can